Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DVC1-0101
- Development stage
- Phase 2
- Lead developer
- DNAVEC
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
DVC1-0101 is a gene therapy medicine designed to treat peripheral arterial disease (PAD). It is based on a recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing the human fibroblast growth factor-2 (FGF-2) gene. The therapy works by delivering the FGF-2 gene to ischemic tissues, promoting angiogenesis (formation of new blood vessels) to improve blood flow in affected areas. This mechanism helps alleviate symptoms like rest pain and limited walking ability in PAD patients.
- Other names
- Angiogenic-gene-therapy-ID-PharmaFibroblast growth factor 2 gene therapy - ID Pharma
02
Targets
FGFR (FGFR family)
Beyond the preview
Go deeper on DVC1-0101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DVC1-0101.